Novanta Announces Financial Results for the First Quarter 2020

• First Quarter 2020 GAAP Revenue of $155.5 million
• First Quarter 2020 GAAP Net Income of $11.9 million
• First Quarter 2020 GAAP Diluted Earnings Per Share of $0.34
• First Quarter 2020 Adjusted Earnings Per Share of $0.51
• First Quarter 2020 Adjusted EBITDA of $27.6 million

BEDFORD, Mass.–(BUSINESS WIRE)–Novanta Inc. (Nasdaq: NOVT) (the “Company”), a trusted technology partner to medical and advanced technology equipment manufacturers, today reported financial results for the first quarter 2020.

*Reconciliations of GAAP to non-GAAP financial measures, as well as definitions for the non-GAAP financial measures included in this press release and the reasons for their use, are presented below.

First Quarter

“We are pleased with the company’s performance in the first quarter, especially considering the significant challenges caused by the COVID-19 pandemic. In the first quarter, we delivered above our guidance for revenue, Adjusted EBITDA, and Adjusted EPS, and I am very proud of how our employees have stepped up and pulled together in the face of adversity,” said Matthijs Glastra, Chief Executive Officer of Novanta. “Our most important concern is the health and well-being of our employees, and we have taken swift actions to ensure their safety. Around the world, all of our factories continue to operate, delivering essential products to our customers who serve medical end markets. We have taken decisive actions to protect our employees, our operations, and our financial position, to help weather the current downturn, and emerge strong when the global economy begins to recover.”

During the first quarter of 2020, Novanta generated GAAP revenue of $155.5 million, a decrease of $1.7 million, or 1.1%, versus the first quarter of 2019. The Company’s acquisition activities resulted in an increase in revenue of $6.6 million, or 4.2%, compared to the first quarter of 2019. Changes in foreign currency exchange rates year over year adversely impacted our revenue by $1.5 million, or 1.0%, during the first quarter of 2020. Our year-over-year Organic Revenue Growth, which excludes the net impact of acquisitions and changes in foreign currency exchange rates, was a decrease of 4.3% for the first quarter of 2020 (see “Organic Revenue Growth” in the non-GAAP reconciliations below).

In the first quarter of 2020, GAAP operating income was $13.3 million, compared to $14.4 million in the first quarter of 2019. GAAP net income was $11.9 million in the first quarter of 2020, compared to $12.3 million in the first quarter of 2019. GAAP diluted earnings per share (“EPS”) was $0.34 in the first quarter of 2020, compared to $0.35 in the first quarter of 2019.

Adjusted Diluted EPS was $0.51 in the first quarter of 2020, compared to $0.53 in the first quarter of 2019. The Company ended the first quarter of 2020 with 35.6 million diluted weighted average shares outstanding. Adjusted EBITDA was $27.6 million in the first quarter of 2020, compared to $28.2 million in the first quarter of 2019.

Operating cash flow for the first quarter of 2020 was $17.6 million, compared to $5.5 million in the first quarter of 2019. The Company completed the first quarter of 2020 with approximately $211.6 million of total debt and $73.7 million of total cash. Net Debt, as defined in the non-GAAP reconciliation below, was $143.1 million.

Financial Position

Novanta believes it has a strong balance sheet and has positioned the Company well to weather the economic disruptions caused by the COVID-19 pandemic. The Company believes that it has ample liquidity, with approximately $74 million in cash and cash equivalents as of the first quarter of 2020, and $375 million borrowing capacity under the Company’s revolving credit facility. The Company has no debt maturing until December 2024. In addition, the Company has focused its near-term financial objectives on maximizing free cash flow and Adjusted EBITDA to position the Company well for the eventual recovery from the pandemic.

Given this, Novanta continues to focus on capital allocation decisions that drive our long-term strategies, including investing in our people, our capabilities and culture, investing in our new product development pipeline, as well as actively looking for the right strategic acquisition opportunities.

“While we expect the short-term impact of the pandemic to our financial results to be significant, it is consistent with what our customers will see across more than 45 different application areas,” said Robert Buckley, Chief Financial Officer. “We continue to lean into the near-term headwinds, as we are confident this will position us well in a recovery and thereafter. We remain focused on leveraging our financial strength and our innovation to further our relationships with our customers, on attracting and retaining the best talent, and on identifying additional innovative companies to welcome to the Novanta family.”

Financial Guidance

For the second quarter of 2020, the Company expects GAAP revenue of approximately $130 million to $142 million. “In the first quarter, we saw strong bookings and shipments across the board, mostly driven by customers who wanted to secure additional inventory to protect against pandemic caused supply disruptions,” said Matthijs Glastra, “Although this led to strong performance in the first quarter, we believe it will result in lower sales in the second quarter. Regardless, our balance sheet is strong, as is our innovation line-up, and our portfolio is well positioned with exposure to long term secular trends in robotics and automation, healthcare productivity and precision medicine.”

Due to the impact of the COVID-19 pandemic on Novanta’s business, the uncertain duration and scope of the pandemic, and the uncertain timing of the global public health and economic recovery, the Company is not able at this time to reliably estimate the future impact on its operations and other financial results, including for the full year 2020.

Conference Call Information

The Company will host a conference call on Tuesday, May 12, 2020 at 10:00 a.m. ET to discuss these results. To access the call, please dial (888) 346-3959 prior to the scheduled conference call time. Alternatively, the conference call can be accessed online via a live webcast on the Presentations and Events page of the Investor Relations section of the Company’s website at www.novanta.com.

A replay of the audio webcast will be available approximately three hours after the conclusion of the call on the Investor Relations section of the Company’s website at www.novanta.com. The replay will remain available until Monday, July 6, 2020.

Use of Non-GAAP Financial Measures

The non-GAAP financial measures used in this press release are Organic Revenue Growth, Adjusted Gross Profit, Adjusted Gross Profit Margin, Adjusted Operating Income and Operating Margin, Adjusted Income before Income Taxes, Adjusted Income Tax Provision/(Benefit) and Effective Tax Rate, Adjusted Consolidated Net Income, Adjusted Diluted EPS, Adjusted EBITDA, Adjusted EBITDA Margin, Free Cash Flow, Free Cash Flow as a Percentage of Consolidated Net Income and Net Debt.

The Company believes that these non-GAAP financial measures provide useful and supplementary information to investors regarding the operating performance of the Company. It is management’s belief that these non-GAAP financial measures would be particularly useful to investors because of the significant changes that have occurred outside of the Company’s day-to-day business in accordance with the execution of the Company’s strategy. This strategy includes streamlining the Company’s existing operations through site and functional consolidations, strategic divestitures and product line closures, expanding the Company’s business through significant internal investments, and broadening the Company’s product and service offerings through acquisition of innovative and complementary technologies and solutions. The financial impact of certain elements of these activities, particularly acquisitions, divestitures, and site and functional restructurings, is often large relative to the Company’s overall financial performance and can adversely affect the comparability of its operating results and investors’ ability to analyze the business from period to period.

The Company’s Adjusted EBITDA and Organic Revenue Growth are used by management to evaluate operating performance, communicate financial results to the Board of Directors, benchmark results against historical performance and the performance of peers, and evaluate investment opportunities, including acquisitions and divestitures. In addition, Adjusted EBITDA and Organic Revenue Growth are used to determine bonus payments for senior management and employees. The Company also uses Adjusted Diluted EPS as a measurement for performance shares issued to certain executives. Accordingly, the Company believes that these non-GAAP financial measures provide greater transparency and insight into management’s method of analysis.

Non-GAAP financial measures should not be considered as substitutes for, or superior to, measures of financial performance prepared in accordance with GAAP. They are limited in value because they exclude charges that have a material effect on the Company’s reported results and, therefore, should not be relied upon as the sole financial measures to evaluate the Company’s financial results. The non-GAAP financial measures are meant to supplement, and to be viewed in conjunction with, GAAP financial measures. Investors are encouraged to review the reconciliation of these non-GAAP financial measures to their most directly comparable GAAP financial measures as provided in the tables accompanying this press release.

Safe Harbor and Forward-Looking Information

Certain statements in this release are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 and are based on current expectations and assumptions that are subject to risks and uncertainties. All statements contained in this news release that do not relate to matters of historical fact should be considered forward-looking statements, and are generally identified by words such as “expect,” “intend,” “anticipate,” “estimate,” “believe,” “future,” “could,” “should,” “plan,” “aim,” and other similar expressions. These forward-looking statements include, but are not limited to, statements regarding anticipated financial performance, including our financial outlook for the second quarter 2020; our estimates of the impact of the COVID-19 pandemic on our revenues; the Company’s liquidity position to weather and recover from the disruptions caused by the COVID-19 pandemic; expectations regarding market conditions; our product development pipeline; acquisition opportunities; and other statements that are not historical facts.

These forward-looking statements are neither promises nor guarantees, but involve risks and uncertainties that may cause actual results to differ materially from those contained in the forward-looking statements. Our actual results could differ materially from those anticipated in these forward-looking statements for many reasons, including, but not limited to, the following: economic and political conditions and the effects of these conditions on our customers’ businesses and level of business activity; our significant dependence upon our customers’ capital expenditures, which are subject to cyclical market fluctuations; our dependence upon our ability to respond to fluctuations in product demand; our ability to continually innovate and successfully commercialize our innovations; failure to introduce new products in a timely manner; customer order timing and other similar factors beyond our control; disruptions or breaches in security of our information technology systems; our failure to comply with data privacy regulations; changes in interest rates, credit ratings or foreign currency exchange rates; risks associated with our operations in foreign countries; risks associated with the COVID-19 pandemic and events outside our control; risks associated with increased outsourcing of components manufacturing; our exposure to increased tariffs, trade restrictions or taxes on our products; our failure to comply with local import and export regulations in the jurisdictions in which we operate; negative effects on global economic conditions, financial markets and our business as a result of the United Kingdom’s withdrawal from the European Union and the actions of the current U.S. government, including its policies on trade tariffs and reactions from other countries to any new tariffs imposed by the U.S.; violations of our intellectual property rights and our ability to protect our intellectual property against infringement by third parties; risk of losing our competitive advantage; our failure to successfully integrate recent and future acquisitions into our businesses; our ability to attract and retain key personnel; our restructuring and realignment activities and disruptions to our operations as a result of consolidation of our operations; product defects or problems integrating our products with other vendors’ products; disruptions in the supply of certain key components or other goods from our suppliers; our failure to accurately forecast component and raw material requirements leading to excess inventories or interruptions and delays in the delivery of our products to customers; production difficulties and product delivery delays or disruptions; our exposure to medical device regulation, which may impede or hinder the approval or sale of our products and, in some cases, may ultimately result in an inability to obtain approval of certain products or may result in the recall or seizure of previously approved products; potential penalties for violating foreign, U.S. federal, and state healthcare laws and regulations; changes in governmental regulations affecting our businesses or products; our failure to comply with environmental regulations; our failure to implement new information technology systems and software successfully; our failure to realize the full value of our intangible assets; our exposure to the credit risk of some of our customers and in weakened markets; our reliance on third party distribution channels; being subject to U.S. federal income taxation even though we are a non-U.S. corporation; changes in tax laws, and fluctuations in our effective tax rates; any need for additional capital to adequately respond to business challenges or opportunities and repay or refinance our existing indebtedness, which may not be available on acceptable terms or at all; our existing indebtedness limiting our ability to engage in certain activities; volatility in the market price for our common shares; and our failure to maintain appropriate internal controls in the future.

Other important risk factors that could affect the outcome of the events set forth in these statements and that could affect the Company’s operating results and financial condition are discussed in Item 1A of our Annual Report on Form 10-K for the fiscal year ended December 31, 2019, as updated by our Quarterly Report on Form 10-Q for the quarter ended April 3, 2020, our subsequent filings with the Securities and Exchange Commission (“SEC”), and in our future filings with the SEC. Such statements are based on the Company’s beliefs and assumptions and on information currently available to the Company. The Company disclaims any obligation to publicly update or revise any such forward-looking statements as a result of developments occurring after the date of this document except as required by law.

About Novanta

Novanta is a leading global supplier of core technology solutions that give medical and advanced industrial original equipment manufacturers (“OEMs”) a competitive advantage. We combine deep proprietary technology expertise and competencies in photonics, vision, and precision motion with a proven ability to solve complex technical challenges. This enables Novanta to engineer core components and sub-systems that deliver extreme precision and performance, tailored to our customers’ demanding applications. The driving force behind our growth is the team of innovative professionals who share a commitment to innovation and customer success. Novanta’s common shares are quoted on Nasdaq under the ticker symbol “NOVT.”

More information about Novanta is available on the Company’s website at www.novanta.com. For additional information, please contact Novanta Investor Relations at (781) 266-5137 or InvestorRelations@novanta.com.

Contacts

Novanta Inc.
Investor Relations Contact:

Robert J. Buckley

(781) 266-5137

Read full story here